Quantcast

Latest Lymphoma Stories

2014-10-23 08:34:28

Additional test for susceptibility in certain types of lymphoma FT. MYERS, Fla., Oct. 23, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has launched new tests for the detection of mutations in the Bruton tyrosine kinase (BTK) and PLC-gama2 genes for predicting acquired resistance to BTK inhibitors. In addition, NeoGenomics launched a lymphoma profiling test specifically to predict susceptibility...

2014-10-21 12:32:21

WHITE PLAINS, N.Y., Oct. 21, 2014 /PRNewswire-USNewswire/ -- For the second year, The Leukemia & Lymphoma Society (LLS) will award funding to leading scientists and researchers who show promise in developing new drug therapies through the Screen to Lead Program. The collaborative program aims to support academic laboratories pursuing research directed towards medicinal chemistry and/or drug target screening in blood cancers. Members of a peer review panel select projects for...

2014-10-20 16:27:17

WHITE PLAINS, N.Y., Oct. 20, 2014 /PRNewswire-USNewswire/ -- Six academic investigators will receive grants from The Leukemia & Lymphoma Society (LLS) to support innovative ideas that that have the potential to take research in a new direction and fundamentally impact the future of blood cancer diagnosis and treatment. The second-year grant program, called The New Idea Award, looks to identify novel research strategies that involve the exploration of untested but potentially...

2014-10-20 08:31:48

Filing completed just three months after receipt of third FDA approval SUNNYVALE, Calif., Oct. 20, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) based on data from a Phase 2 study evaluating the use of IMBRUVICA(®) (ibrutinib) in patients with Waldenstrom's macroglobulinemia (WM), which was led by Dr. Steven Treon from the Dana-Farber Cancer...

2014-10-15 16:30:22

University of Pennsylvania and Children's Hospital of Philadelphia Research Team Funded by LLS for More Than 22 Years Report Today in New England Journal of Medicine that 90 Percent of Patients Achieved Complete Remission WHITE PLAINS, N.Y., Oct. 15, 2014 /PRNewswire-USNewswire/ -- Funding from The Leukemia & Lymphoma Society (LLS) over the past 22 years helped advance a study published today in the New England Journal of Medicine showing that 90 percent of children and adults...

2014-10-15 04:22:13

EAST ANGUS, Quebec, October 15, 2014 /PRNewswire/ -- facebook.com/trouvonsundonneur [http://www.facebook.com/trouvonsundonneur ] facebook.com/UKyoucansaveMarcAndreSkelling [http://www.facebook.com/UKyoucansaveMarcAndreSkelling ] Marc-Andre Skelling, a 23-year-old young man needs a stem cell donor in order to save his life. Marc-Andre has been diagnosed with Hodgkin disease, a type of lymphoma, which is a cancer originating from white blood cells called...

2014-10-14 12:30:31

NEW BRUNSWICK, N.J., Oct. 14, 2014 /PRNewswire-USNewswire/ -- Actinobac Biomed Inc., has received a $905,040 Small Business Technology Transfer Grant (STTR) Phase II Award from the National Institutes of Health/ National Cancer Institute to continue to develop its drug candidate, Leukothera®, as a potential treatment for B-cell lymphomas. "This NIH grant supports our assertion that Actinobac scientists are working on breakthrough research that can make a tremendous difference for...

2014-10-10 12:24:18

Investigators' Oral and Poster Presentations Highlight Canine Lymphoma Antibody Programs KANSAS CITY, Kan., Oct. 10, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals, today announced its first appearance at the Annual Veterinary Cancer Society meeting this weekend in St. Louis, MO. Investigators presented data on monoclonal...

2014-10-10 08:24:12

DUBLIN, Oct. 10, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Non-Hodgkin lymphoma (NHL) is a condition of the human body leading to the production of abnormal lymphocytes. In normal circumstances, the lymphocytes grow and die. However, in NHL they do not die; instead they grow and further divide. NHL can begin either in the...

2014-09-26 23:02:21

New research report “Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting” elaborated by GBI Research is now available at MarketPublishers.com. According to the study, the APAC market for non-Hodgkin lymphoma is poised for growth at a 6.6% CAGR. London, UK (PRWEB) September 26, 2014 The APAC non-Hodgkin lymphoma therapeutics market is expected to grow from USD 1.1 billion as of 2013 to the USD...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related